L-dopa-induced dyskinesia: Beyond an excessive dopamine tone in the striatum

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Porras, Gregory ^a,b,c   De Deurwaerdere, Philippe ^a,b   Li, Qin ^c,d   Marti, Matteo ^e   Morgenstern, Rudolf ^f   Sohr, Reinhard ^f   Bezard, Erwan ^a,b,c,d,g   Morari, Michele ^e   Meissner, Wassilios G ^a,b,g,h  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^c Williams House   (United Kingdom)

^d INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^e UNIVERSITY OF FERRARA   (Italy)

^f HUMBOLDT UNIVERSITY   (Germany)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h Centre de Référence AMS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE; BENSERAZIDE, LEVODOPA DRUG COMBINATION; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG COMBINATION; LEVODOPA;

ANIMAL; CORPUS STRIATUM; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; DYSKINESIAS; FEMALE; MALE; METABOLISM; PARKINSON DISEASE; RHESUS MONKEY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BENSERAZIDE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DRUG COMBINATIONS; DYSKINESIAS; FEMALE; LEVODOPA; MACACA MULATTA; MALE; PARKINSON DISEASE;

EID: 84892742650     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03730     Document Type: Article

References (36)

1. Carta, M. & Bezard, E. Contribution of pre-synaptic mechanisms to L-DOPAinduced dyskinesia. Neuroscience 198, 245-251 (2011).
2. DeLong, M. R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281-285 (1990).
3. Marti, M. et al. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPAinduced dyskinesias. J Neurosci 32, 16106-16119 (2012).
4. de la Fuente-Fernandez, R. et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127, 2747-2754 (2004). (Pubitemid 39627382)
5. Misu, Y., Goshima, Y., Ueda, H. & Okamura, H. Neurobiology of L-DOPAergic systems. Prog.Neurobiol. 49, 415-454 (1996). (Pubitemid 26312772)
6. Goshima, Y., Kubo, T. & Misu, Y. Biphasic actions of L-DOPA on the release of endogenous noradrenaline and dopamine from rat hypothalamic slices. Br J Pharmacol 89, 229-234 (1986). (Pubitemid 16031223)
7. Misu, Y. & Goshima, Y. Is L-dopa an endogenous neurotransmitter? Trends Pharmacol Sci 14, 119-123 (1993). (Pubitemid 23113116)
8. Alachkar, A., Brotchie, J. M. & Jones, O. T. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites. Neurosci Res 68, 44-50 (2010).
9. Nakazato, T. & Akiyama, A. Effect of exogenous L-dopa on behavior in the rat: an in vivo voltammetric study. Brain Res 490, 332-338 (1989). (Pubitemid 19158565)
10. Buck, K. & Ferger, B. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Neuroscience 159, 16-20 (2009).
11. Buck, K., Voehringer, P. & Ferger, B. Site-specific action of L-3, 4- dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3, 4- dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats. Neuroscience 166, 355-358 (2010).
12. Buck, K.&Ferger, B. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Neurobiol Dis 29, 210-220 (2008).
13. Marti, M., Trapella, C., Viaro, R. & Morari, M. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci 27, 1297-1307 (2007).
14. Stefani, A. et al. The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus. Cell Death Dis 2, e154 (2011).
15. Fernagut, P. O. et al. Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. PLoS One 5, e14053 (2010).
16. Guigoni, C. et al. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur J Neurosci 22, 283-287 (2005). (Pubitemid 41059995)
17. Navailles, S., Bioulac, B., Gross, C. & De Deurwaerdere, P. Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol Dis 38, 136-143 (2010).
18. Meissner, W. et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol.Dis. 22, 586-598 (2006). (Pubitemid 43832130)
19. Ruottinen, H. M. & Rinne, U. K. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 60, 36-40 (1996). (Pubitemid 26012264)
20. Hauser, R. A. et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord 26, 2246-2252 (2011).
21. Gil, S., Park, C., Lee, J. & Koh, H. The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in aHemiparkinsonian rat model. Cell Mol Neurobiol 30, 817-825 (2010).
22. Yee, R. E. et al. Nigrostriatal reduction of aromatic L-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: in vivo and in vitro investigations. J Neurochem 74, 1147-1157 (2000). (Pubitemid 30104312)
23. Stephenson, D. T. et al. Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys. Cell Transplant 16, 229-244 (2007). (Pubitemid 47300229)
24. Lloyd, K. G., Davidson, L.&Hornykiewicz, O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 195, 453-464 (1975).
25. Tanaka, H. et al. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10, 631-634 (1999). (Pubitemid 29333295)
26. Carta, M., Carlsson, T., Kirik, D. & Bjorklund, A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 1819-1833 (2007). (Pubitemid 47343795)
27. Pifl, C., Schingnitz, G. & Hornykiewicz, O. Effect of 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44, 591-605 (1991).
28. Munoz, A. et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 131, 3380-3394 (2008).
29. Navailles, S., Bioulac, B., Gross, C. & De Deurwaerdere, P. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol Dis 41, 585-590 (2011).
30. Fox, S. H., Johnston, T. H., Li, Q., Brotchie, J. & Bezard, E. A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale. Mov Disord 27, 1373-1378 (2012).
31. Porras, G., Li, Q. & Bezard, E. Modeling Parkinson's Disease in Primates: The MPTP Model. Cold Spring Harb Perspect Med 2, a009308 (2012).
32. Meissner, W. G. et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 10, 377-393 (2011).
33. Kish, S. J. et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 131, 120-131 (2008).
34. Ahmed, M. R. et al. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med 2, 28ra28 (2010).
35. Porras, G. et al. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest 122, 3977-3989 (2012).
36. Bezard, E. et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9, 762-767 (2003). (Pubitemid 36749227)